* Zymeworks Inc ZYME.OQ ZYME.O is expected to show a
rise in
quarterly revenue when it reports results on August 1 for the
period ending June 30 2024
* The Middletown Delaware-based company is expected to
report a
187.0% increase in revenue to $20.092 million from $7 million a
year ago, according to the mean estimate from 7 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Zymeworks Inc is for a
loss
of 32 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Zymeworks
Inc is
$14.00, above its last closing price of $10.42.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.29 -0.29 -0.42 Missed -44.8
Dec. 31 2024 -0.46 -0.43 -0.20 Beat 53.9
Jan. 1 0001 -0.50 -0.47 -0.41 Beat 12.7
Jun. 30 2023 -0.49 -0.47 -0.76 Missed -61.6
Mar. -0.55 -0.54 -0.36 Beat 32.9
31 2023
Dec. 31 2022 4.44 4.84 4.65 Missed -3.9
Sep. 30 2022 -0.91 -0.92 -0.72 Beat 21.8
Jun. 30 2022 -0.94 -0.96 -0.97 Missed -0.7
This summary was machine generated July 31 at 01:07 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)